TRK Inhibitors in Lung and GI Cancers

home / peer-exchange / trk-inhibitors-in-lung-and-gi-cancers

Role of NTRK Inhibitors

EP. 1: Role of NTRK Inhibitors

By John L. Marshall, MD, MedStar Georgetown University Hospital
Tanios S. Bekaii-Saab, MD, Mayo Clinic

Variants of NTRK Fusions in Solid Tumors

EP. 2: Variants of NTRK Fusions in Solid Tumors

By John L. Marshall, MD, MedStar Georgetown University Hospital
Tanios S. Bekaii-Saab, MD, Mayo Clinic

Evolution of NGS Testing in Lung Cancers

EP. 3: Evolution of NGS Testing in Lung Cancers

By John L. Marshall, MD, MedStar Georgetown University Hospital
Tanios S. Bekaii-Saab, MD, Mayo Clinic

Using Molecular Testing in GI Cancers

EP. 4: Using Molecular Testing in GI Cancers

By John L. Marshall, MD, MedStar Georgetown University Hospital
Tanios S. Bekaii-Saab, MD, Mayo Clinic

Approaching Genomic Testing for NTRK Fusions

EP. 5: Approaching Genomic Testing for NTRK Fusions

By John L. Marshall, MD, MedStar Georgetown University Hospital
Tanios S. Bekaii-Saab, MD, Mayo Clinic

Genomic Testing for NTRK Fusions in Lung and GI Cancers

EP. 6: Genomic Testing for NTRK Fusions in Lung and GI Cancers

By John L. Marshall, MD, MedStar Georgetown University Hospital
Tanios S. Bekaii-Saab, MD, Mayo Clinic

Driver Mutations in NTRK Fusion-Positive Cancers

EP. 7: Driver Mutations in NTRK Fusion-Positive Cancers

By John L. Marshall, MD, MedStar Georgetown University Hospital
Tanios S. Bekaii-Saab, MD, Mayo Clinic

Advice for Interpreting NGS Reports

EP. 8: Advice for Interpreting NGS Reports

By John L. Marshall, MD, MedStar Georgetown University Hospital
Tanios S. Bekaii-Saab, MD, Mayo Clinic

Early Development of TRK Inhibitors

EP. 9: Early Development of TRK Inhibitors

By John L. Marshall, MD, MedStar Georgetown University Hospital
Tanios S. Bekaii-Saab, MD, Mayo Clinic

Efficacy of TRK Inhibitors

EP. 10: Efficacy of TRK Inhibitors

By John L. Marshall, MD, MedStar Georgetown University Hospital
Tanios S. Bekaii-Saab, MD, Mayo Clinic

EP. 11: TRK Inhibitor in GI Cancers: Adverse Effect Profile

By John L. Marshall, MD, MedStar Georgetown University Hospital
Tanios S. Bekaii-Saab, MD, Mayo Clinic

Approaching Treatment for TRK Fusion–Positive Cancers

EP. 12: Approaching Treatment for TRK Fusion–Positive Cancers

By John L. Marshall, MD, MedStar Georgetown University Hospital
Tanios S. Bekaii-Saab, MD, Mayo Clinic

Acquired Resistance in TRK Fusion-Positive Cancers

EP. 13: Acquired Resistance in TRK Fusion-Positive Cancers

By John L. Marshall, MD, MedStar Georgetown University Hospital
Tanios S. Bekaii-Saab, MD, Mayo Clinic

Challenges for TRK Fusion–Targeting Agents

EP. 14: Challenges for TRK Fusion–Targeting Agents

By John L. Marshall, MD, MedStar Georgetown University Hospital
Tanios S. Bekaii-Saab, MD, Mayo Clinic

Future of NTRK Fusions

EP. 15: Future of NTRK Fusions

By John L. Marshall, MD, MedStar Georgetown University Hospital
Tanios S. Bekaii-Saab, MD, Mayo Clinic

Latest Conference Coverage

Belumosudil Produces Long-Term Responses Without New Safety Concerns in cGVHD

Prophylactic Itacitinib May Safely Mitigate CRS Following Axi-Cel Administration in Lymphoma

Serial ctDNA Testing Could Improve Risk Stratification in High-Risk MIBC

Adjuvant Nivolumab Provides Sustained DFS Benefit, Favors OS in Muscle-Invasive Urothelial Cancer

View More Latest Conference Coverage

Editorial Board

CancerNetwork.com

OncNursingNews.com

TargetedOnc.com

Terms & Conditions

Do Not Sell My Information

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

© 2024 MJH Life Sciences

All rights reserved.